Harrow, Inc. (NASDAQ:HROW) Shares Sold by Woodmont Investment Counsel LLC

Woodmont Investment Counsel LLC lessened its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 60.7% in the 3rd quarter, Holdings Channel reports. The firm owned 80,955 shares of the company’s stock after selling 124,908 shares during the period. Woodmont Investment Counsel LLC’s holdings in Harrow were worth $3,640,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets grew its position in shares of Harrow by 12.7% in the first quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock valued at $224,000 after purchasing an additional 1,912 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Harrow by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock valued at $24,208,000 after purchasing an additional 21,253 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Harrow by 6.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock valued at $221,000 after purchasing an additional 1,033 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in shares of Harrow in the first quarter valued at approximately $185,000. Finally, Opaleye Management Inc. increased its holdings in shares of Harrow by 2.6% in the first quarter. Opaleye Management Inc. now owns 3,920,600 shares of the company’s stock valued at $51,870,000 after purchasing an additional 100,600 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th. B. Riley reaffirmed a “buy” rating and issued a $50.00 price target on shares of Harrow in a report on Thursday, August 29th. Finally, Craig Hallum increased their price target on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 4th.

Harrow Trading Up 5.3 %

Shares of Harrow stock opened at $48.24 on Thursday. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -50.78 and a beta of 0.76. Harrow, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60. The stock has a 50 day moving average of $46.70 and a 200 day moving average of $30.57.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. The company had revenue of $48.94 million during the quarter, compared to analyst estimates of $42.78 million. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. As a group, research analysts predict that Harrow, Inc. will post 0.09 earnings per share for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.